The second annual Lupus Insight Prize, presented in a collaboration among the Alliance for Lupus Research (ALR), the Lupus Foundation of America (LFA) , and the Lupus Research Institute (LRI) will be awarded by the three organizations to recognize and honor an outstanding investigator with a documented record of creativity, innovation, and productivity. The researcher will also be someone who has made a novel insight in an area of research that is applicable to the pathogenesis or treatment of lupus and is judged to have a high likelihood of generating further advances by applying that insight to lupus.
The 2014 Lupus Insight Prize recipient will be awarded $200,000 to be used for research dedicated to advancing understanding of the genetic, environmental, molecular, immunologic or cellular aspects of lupus and/or its treatment. The Prize must be utilized within three years from the date it is awarded.
Nominations will be reviewed by members of an independent Selection Committee comprised of representatives of the three funding lupus organizations. The Committee will review nominations and award the Prize based on a variety of criteria, including academic achievements, creativity, insight, and potential for future advances that will impact people with lupus.
The full application must be submitted by the Nominator and the Candidate electronically by February 20, 2014 at 5 p.m. ET, The Prize recipient will be announced and honored publicly at the FOCIS Meeting on June 25, 2014 in a ceremony hosted by the three organizations.
The Lupus Insight Prize is awarded to an outstanding investigator who has developed novel research insight in scientific domains relevant to lupus.
Dr. Bruce Richardson recipient of the 2014 Lupus Insight Prize
The institution of the Prize recipient will receive $200,000 to be used at the discretion of the recipient scientist with the expectation that those funds will be applied to research dedicated to advancing understanding of the genetic, environmental, molecular, immunologic or cellular aspects of lupus and/or its treatment. The Prize can be transferred to another institution (within the U.S.) in the event
Nominations for the Lupus Insight Prize should represent collaboration between the Nominator and Candidate. Nominations of basic, clinical, and translational scientists will be considered. Candidates can be investigators of any age or rank affiliated with an academic, biomedical, research, or government institution in the United States. Nominations will not be accepted for investigators working in the biotechnology or pharmaceutical industries. Additionally, Candidates may not already possess a grant award to pursue the aims described in the application for the Prize. Co-investigators or teams of investigators are not eligible for the Lupus Insight Prize.
Nominators and Candidates should work together to prepare each Candidate's Letter of Nomination for The Lupus Insight Prize. Nominations of basic, clinical, and translational scientists will be considered. The Nominator should submit a two-page Letter of Nomination, describing the worthiness, expertise and achievements of the Candidate and specifically focus on the unique insight generated by the Candidate that might have an impact on advancing the future of lupus research. The letter of Nomination should clearly state the insight for which the candidate is being nominated.
- a description of the novel hypothesis, innovative concept, or unusually creative experimental approach that will be applied to lupus by the Candidate
- anticipated goal of the proposed project
- potential impact of the proposed research on the field as a whole, as well as its potential to galvanize, change, and/or revolutionize lupus research or treatment
The Research Narrative should not be considered as a grant application, but should describe the applicant's unique insight and its potential to move lupus research forward. The Research Narrative should be a stand-alone document and cannot include any web links to additional materials. Appendices will not be accepted.
In addition to the Research Narrative, the Candidate should also submit a complete CV. Two blind letters in support of the Candidate (from people other than the Nominator) must also be solicited by the Candidate, and each must be submitted directly via proposalCENTRAL by the individual writing each letter. The application will not be considered complete without the two blind letters in support of the Candidate.
Each full application must be received electronically by February 20, 2014 at 5 p.m. ET via Altumís proposalCENTRAL online system at https://proposalcentral.altum.com/. Hard copies will not be accepted under any circumstances.
Dr. Bruce Richardson Selected as the Second Recipient of the
Lupus Insight Prize
CHICAGO, IL -- Bruce Richardson, M.D., Ph.D., of the University of Michigan, was honored Wednesday as the second recipient of the Lupus Insight Prize, the award for use in innovative research on lupus, an unpredictable and sometimes fatal autoimmune disease that affects an estimated 1.5 million Americans. Dr. Richardson received the Prize during a formal ceremony at FOCIS 2014, the 14th Annual Meeting of the Federation of Clinical Immunology Societies in Chicago.
The Prize is a collaborative initiative among the Alliance for Lupus Research, the Lupus Foundation of America, and the Lupus Research Institute to recognize and honor the achievements of an outstanding investigator in the field whose research efforts have made significant contributions and have a high likelihood of generating further insights in understanding the causes, biology, treatments, or cure of lupus.
“I would like to thank the Alliance for Lupus Research, the Lupus Foundation of America and the Lupus Research Institute for this honor. The award will allow us to identify epigenetically regulated gene products that may be targets for new lupus treatments, characterize how environmental stressors and diet affect lupus flare severity, and identify new ways to prevent lupus flares,” said Dr. Richardson. “I would also like to thank all the people who worked in my laboratory and made these studies successful, and the others in the fields of epigenetics and autoimmunity that provided the foundations for this work.”
Epigenetics looks at the mechanisms that turn genes on or off. These modifications may occur naturally or as a result of external factors including age, environment, lifestyle and disease state. Dr. Richardson discovered that some lupus-causing drugs alter gene activity or expression in normal “helper” lymphocytes, converting them into autoreactive “killer” lymphocytes that attack other cells and cause lupus in mice. He also found the same changes in gene expression in lymphocytes from patients with active lupus, and that many of the environmental agents implicated in lupus, as well as diet, contribute to the changes by altering gene expression. With the award funds, Dr. Richardson will identify the genes affected by environmental agents, and determine how these environmental agents and diet cause changes in lymphocytes.
Lupus Research Institute President and CEO Margaret Dowd commented, “Dr. Richardson’s pioneering work laid the foundation for the study of epigenetics in lupus and autoimmunity. He continues to study how environmental exposures, genetic factors and epigenetic changes interact to trigger lupus disease and flares.”
“Dr. Richardson’s research will help to identify potential new approaches to managing lupus and gives us new targets for developing drug therapies,” said Sandra Raymond, President and CEO of the Lupus Foundation of America. “It also will provide clearer insight into which environmental factors are important in triggering lupus.”
“All of the organizations involved in this effort want to quickly improve the well-being of the 1.5 million Americans living with lupus and countless others who are affected by it,” said Kenneth Farber, President of the Alliance for Lupus Research. “Working together with the other organizations and with innovators in their field to focus on our common goal to accelerate progress is the way that we are going to make a strong impact.”
Additional information about the Lupus Insight Prize and Dr. Richardson’s work in lupus are available online at www.lupusinsightprize.org. Information on the application process for the 2015 Prize will be posted in the coming weeks.
Lupus is a chronic autoimmune disease that causes inflammation and tissue damage to any organ system in the body. The health effects of lupus include heart attacks, strokes, seizures, organ failure, and possible death. An estimated 1.5 million Americans and at least five million people worldwide have lupus.
About the Funding Organizations
For more information about the Alliance for Lupus Research, visit www.lupusresearch.org.
For more information about the Lupus Foundation of America, visit www.lupus.org.
For more information about the Lupus Research Institute, visit www.lupusresearchinstitute.org.
FOCIS exists to improve human health through immunology by fostering interdisciplinary approaches to understand and treat immune-based diseases. FOCIS 2014 is the 14th Annual Meeting of the Federation of Clinical Immunology Societies in Boston, where scientists will present their findings on lupus and other diseases affecting the immune system. Thirty different specialties will be represented and over three hundred scientific papers will be presented.
Courtney Love, Alliance for Lupus Research, firstname.lastname@example.org, 212-218-2869
Duane Peters, Lupus Foundation of America, email@example.com, 202-349-1145
Margy Meislin, Lupus Research Institute, firstname.lastname@example.org, 212-685-4118 x 34
Sarah Martis, Federation of Clinical Immunology Societies, email@example.com, 414-359-1670 x1103
Source: Alliance for Lupus Research
Dr. Mark J. Shlomchik Receives Lupus Insight Prize Recognizing Outstanding Contribution in Lupus Research
JUNE 27, 2013
WASHINGTON, DC -- Mark J. Shlomchik, M.D., Ph.D., the incoming Chair of Immunology at the University of Pittsburgh, was honored Thursday as the first recipient of the Lupus Insight Prize, the first-of-a-kind award for use in innovative research on lupus, an unpredictable and sometimes fatal autoimmune disease that affects an estimated 1.5 million Americans. Dr. Shlomchik received the Prize during a formal ceremony at FOCIS 2013, the 13th Annual Meeting of the Federation of Clinical Immunology Societies in Boston.
The Prize is a collaborative initiative among the Alliance for Lupus Research, the Lupus Foundation of America, and the Lupus Research Institute to recognize and honor the achievements of an outstanding investigator in the field whose research efforts have a high likelihood of generating further advances in understanding the causes, biology, treatments, or cure of lupus.
"I would like to thank the three sponsoring organizations for bestowing this honor upon me," said Dr. Shlomchik. "Lupus is a very complex disease for which I have devoted much of my career. This award will enable me to further my research and make important contributions to understanding and treating this difficult disease."
With the award funds, Dr. Shlomchik will investigate the connection between the death of neutrophils, the body's most abundant white blood cells, and lupus. Many researchers believe lupus is the result of an abnormal immune response to dying cells. To fight infections, neutrophils use a molecule called NADPH oxidase. It was thought that this molecule may cause these neutrophils to die in a way that promotes an autoimmune response. However, to the surprise of most lupus researchers, Dr. Shlomchik discovered that lupus-prone mice that are missing this gene, have markedly worse diseaseóthe opposite of the original theory.
Dr. Shlomchik will create new animal models of lupus that produce neutrophils lacking NADPH oxidase to test how this molecule prevents animals from developing severe lupus. Because NADPH oxidase is turned on by infections, the work could help researchers understand the role infections might play in triggering lupus.
"We are pleased to collaborate with the other organizations to find better ways to manage lupus and, ultimately, to find a cure," said Ken Farber, President of the Alliance for Lupus Research. "By bringing together leaders in their fields, and those with a common focus, we have the opportunity to positively impact the well-being of the 1.5 million Americans with lupus."
"Dr. Shlomchik's work has provided insight into the underlying causes of lupus and has identified pathways for further research," said Sandra Raymond, President and CEO of the Lupus Foundation of America. "Continued support of these research efforts on lupus holds promise of generating further advances in the diagnosis and treatment of this devastating disease."
Lupus Research Institute President and CEO Margaret Dowd commented, "The Lupus Insight Prize recognizes Dr. Shlomchik's outstanding contributions to the field and supports his ability to continue his innovative work. Judging by the exceptional quality of Dr. Shlomchik's work, we can look forward to his further progress in developing novel approaches for new treatments."
Additional information about the Lupus Insight Prize and Dr. Shlomchik's work in lupus are available online at www.lupusinsightprize.org. Information on the application process for the 2014 Prize will be posted in the coming weeks.